Clinical Focus


  • Pediatric Rheumatology

Academic Appointments


Professional Education


  • Fellowship: Medical College of Wisconsin Dept of Pediatrics (2025) WI
  • Board Certification: American Board of Pediatrics, Pediatrics (2018)
  • Residency: University of Chicago Dept of Pediatrics (2018) IL
  • Medical Education: Michigan State University College of Human Medicine (2015) MI

All Publications


  • Clinical Features, Treatments, and Outcomes of an International Cohort of 96 Children with Takayasu Arteritis. ACR open rheumatology Bistolarides, J., Morishita, K. A., Sivaraman, V., Wagner-Weiner, L., Bosman, E. S., McPhate, N., Nocton, J. J., Liegl, M., Pan, A. Y., Beresford, M. W., Charuvanij, S., de Guzman, M., Elder, M., Giani, T., Gagne, S., Harrison, K., James, K., Jelusic, M., Khan, A., Martin, N., Park, J., Rosenberg, A. M., Shenoi, S., Tanner, T., Tarvin, S. E., Twilt, M., Yeung, R. S., Brown, K., Cabral, D. 2026; 8 (11)

    Abstract

    To characterize the clinical features, treatment, and outcomes of a large, international cohort of childhood-onset Takayasu arteritis (cTAK).Patients with a diagnosis of cTAK were identified in A Registry of Childhood Vasculitis and divided into subcohorts by era-of diagnosis: pre-biologic (PB; 1986-2006), early biologic (EB; 2007-2017), and recently diagnosed (RD; 2018-present). Longitudinal patient data were collected at time of diagnosis (TOD), postinduction (PI; 3-6 months after TOD), and 12 months after TOD (12m). Meaningful clinical improvement was defined as at least a 50% reduction in the Pediatric Vasculitis Activity Score. Damage was assessed by the Pediatric Vasculitis Damage Index.Among 96 patients (69% female, median age 12.8 years [interquartile range 9.8-15.3]) from nine countries, 86% showed clinical improvement at PI and 90% maintained improvement at 12m. Glucocorticoids (GC; n = 84, 88%) and methotrexate (n = 47, 49%) were the two most common medications prescribed at TOD, often together and in combination with another medication. GC use continued at 12m in 79%. Patients more recently diagnosed were more likely to receive treatment with tumor necrosis factor inhibitors (0% PB, 26% EB, and 35% RD; P = 0.007) and reach 70% improvement (59% PB, 81% EB, and 100% RD; P = 0.007) at PI. However, neither improvement nor damage at 12m differed among the subcohorts.Although treatment approaches for cTAK have evolved and most patients demonstrate sustained clinical improvement at 12m, these advances have not translated into substantial changes in outcomes, highlighting the need for optimized therapeutic strategies.

    View details for DOI 10.1002/acr2.90146

    View details for PubMedID 42971797

    View details for PubMedCentralID PMC13727717

  • Effective performance of the 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for Antineutrophil-Cytoplasmic-Antibody-Associated Vasculitis in Pediatric Patients: an ARChiVe Study. Arthritis & rheumatology (Hoboken, N.J.) Cabral, D. A., Bosman, E. S., McPhate, N., Mann, S. K., Toor, K. K., Morishita, K. A., Luqmani, R., Beresford, M. W., Bistolarides, J., Campillo, S., Charuvanij, S., Cook, K., Dancey, P., de Guzman, M., Deepak, S., Eberhard, B., Elder, M., Gagne, S., Harrison, K., Huber, A., Khan, A., Kim, S., Klein-Gitelman, M. S., Lee, T. C., Li, S. C., Martin, N., McErlane, F., Moorthy, L. N., Orjuela, A. H., Park, J., Riley, P., Rosenberg, A. M., Shenoi, S., Sivaraman, V., Sutnga, S., Tanner, T., Tarvin, S. E., Twilt, M., Wagner-Weiner, L., Yeung, R. S., Brown, K. L., ARChiVe Investigators Network within the PedVas Initiative 2026

    Abstract

    OBJECTIVE: To assess the 2022-ACR/EULAR classification criteria for ANCA-associated vasculitis (AAV) in children with chronic small-to-medium vessel vasculitis.METHODS: A cohort of 574 patients, identified by physician's-(MD)-diagnosis in A-Registry-of-Childhood-Vasculitis, were classified by computation of registry data, as having granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA) or eosinophilic GPA (EGPA) after applying (1) ACR/EULAR AAV criteria and (2) pediatric-adapted European Medicines Agency (Ped-EMA) classification algorithm (incorporating Ankara GPA criteria). Venn diagrams compared the resulting GPA/MPA cohorts with MD-diagnosis. Sensitivity and specificity of criteria for GPA were evaluated against MD-diagnosis. Fisher's exact test evaluated differences in the frequencies of individual clinical features in GPA versus MPA.RESULTS: Comparing ACR/EULAR criteria against Ped-EMA-algorithm for classifying AAV, respectively, more patients were classified as GPA or MPA (n=396 versus 360), fewer had GPA (n=261 versus 288), more had MPA (135 versus 72), and fewer GPA cases co-classified as MPA (12% versus 28%); there were more differences between GPA and MPA in PVAS-defined clinical features (n=14 versus 10).When classifying GPA by ACR/EULAR or Ankara criteria, respectively sensitivity (74.5% versus 72.1%) was comparable, and specificity for ACR/EULAR criteria (93.9% versus 79.9%) was improved.CONCLUSION: The 2022 ACR/EULAR classification criteria for AAV performs at least as well as previous pediatric criteria and provide categorical MPA criteria where none existed previously; the criteria for GPA and MPA now specifically differentiate each other, with more differences between them in the frequencies of clinical features. Our findings support the preferential use of ACR/EULAR over Ankara criteria for GPA in pediatrics.

    View details for DOI 10.1002/art.70172

    View details for PubMedID 41958151